Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced a significant advancement to its clinical development plan: the PLX cell program in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE